Sarepta Therapeutics, Inc. - Common Stock (SRPT)

CAMBRIDGE, MA — March 26, 2026 — Shares of Sarepta Therapeutics (NASDAQ: SRPT) skyrocketed 35% in early trading today, reaching levels not seen since the company’s early days in Duchenne Muscular Dystrophy (DMD). The massive rally follows the release of highly anticipated Phase 1/2 clinical data for its next-generation siRNA

CAMBRIDGE, MA — March 26, 2026 — Shares of Sarepta Therapeutics (NASDAQ:SRPT) skyrocketed 34.98% in heavy trading today, marking the biotech giant's most explosive single-day gain in over two years. The rally follows the release of breakthrough Phase 1/2 clinical data for its next-generation siRNA candidates, a development that

On March 25, 2026, the biotechnology sector witnessed a tectonic shift as Sarepta Therapeutics (NASDAQ: SRPT) saw its share price skyrocket by 34% in a single trading session. This dramatic surge—the company’s largest single-day gain in nearly a decade—was ignited by groundbreaking Phase 1/2 clinical data from its next-generation siRNA (small interfering RNA) platform. For [...]

As of March 25, 2026, Sarepta Therapeutics (NASDAQ: SRPT) stands at a pivotal, albeit bruising, crossroads in the history of genetic medicine. Once the darling of the biotechnology sector for its aggressive pursuit of treatments for Duchenne Muscular Dystrophy (DMD), the Cambridge-based firm is currently navigating a period of profound transition. After a landmark 2024 [...]

These stocks aren't nearly as cheap as they look.

Data from the study cohort is aimed at determining whether administering sirolimus prior to and after Elevidys infusion can help reduce risks associated with the gene therapy.

Data from Stocktwits showed that retail sentiment on SPY and QQQ diverged.

A new Cohort 8 study aims to reopen the non-walking patient market with data expected by the end of 2026.

Sarepta (SRPT) Q4 2025 Earnings Call Transcript

Institutional support remains strong in February, with 134 investors increasing positions and 61 initiating new stakes.

While Sarepta’s gene therapy for the treatment of DMD called Elevidys was approved by the FDA in 2023, Regenxbio is developing its treatment.

Don't catch a falling knife.

Sarepta Therapeutics announced a debt refinancing plan totaling about $291 million.

New York, NY – December 9, 2025 – Dyne Therapeutics (NASDAQ: DYN) found itself in an unusual spotlight today, emerging as a significant market mover, albeit in a direction that belied ostensibly positive news. Despite announcing highly encouraging clinical trial results for its lead Duchenne muscular dystrophy (DMD) candidate, DYNE-251, the company's

December 3, 2025 – Capricor Therapeutics (NASDAQ: CAPR) has sent shockwaves through the biotech sector today, witnessing an astonishing 535% surge in its stock price, propelling the company to an eight-year high. The dramatic ascent follows the announcement of overwhelmingly positive top-line results from its pivotal Phase 3 HOPE-3 study for

Shares of BridgeBio Pharma are nearing a record high as the small biotech company takes on drug behemoths Pfizer and Alnylam.

The data from the study cohort will be used to determine whether administering sirolimus before and after the ELEVIDYS infusion can help reduce acute liver injury, the company said.

All eyes are on Nvidia Corp. (NASDAQ:NVDA) as the world's most valuable company prepares to report third-quarter earnings after the close, a pivotal moment that could steer